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ABSTRACT
The human SNM1 protein is a member of a highly
conserved group of proteins catalyzing the hydro-
lysis of nucleic acid substrates. Although over-
production is unstable in mammalian cells, we
have overproduced a recombinant hSNM1 protein
in an insect cell system. The protein is a single-
strand 50-exonuclease, like its yeast homolog. The
enzyme utilizes either DNA or RNA substrates,
requires a 50-phosphate moiety, shows very little
activity on double-strand substrates, and functions
at a size consistent with a monomer. The exonu-
clease activity requires the conserved b-lactamase
domain; site-directed mutagenesis of a conserved
aspartate inactivates the exonuclease.
INTRODUCTION
The SNM1 protein belongs to the metallo-b-lactamase
family of proteins, characterized by conserved sequences
for binding Zn
2+ and cleaving substrates with ester
linkages. The b-CASP subfamily (CPSF73, Artemis/
SNM1 (or Pso2), and Elac1 and 2, further have conserved
domains, A, B and C, in addition to the hydrolytic
lactamase domain (1,2). SNM1 is the product of a gene
ﬁrst described in Saccharomyces cerevisiae as PSO2,
a non-essential gene required for normal survival after
exposure to psoralen or other DNA interstrand cross-
linking (ICL) agents such as nitrogen mustard or cisplatin
(3) (4). The SNM1 gene is assigned to the nucleotide
excision repair (NER) pathway (RAD3 epistasis group),
despite the fact that cells deﬁcient in SNM1 protein in
yeast show no increase in sensitivity to other DNA-
damaging agents such as UV or radiation. A defect in
SNM1 in yeast is additive to a defect in the RAD52
pathway (recombination) or the RAD6 pathway (post-
replication) (5), showing that the three DNA repair
epistasis groups in yeast are deﬁned in ICL repair as
well. For mutants defective in all three pathways, a single
ICL is lethal (5).
ICL repair produces double-strand breaks (DSB) and
snm1 yeast mutants incise DNA with ICLs normally (6–8),
showing normal DSB formation. However, intact DNA is
not reformed at normal rates (8) in snm1 mutants, but
HO-induced mating type switching is processed normally
(8), demonstrating that there are speciﬁc features of
ICL-induced DSBs which require SNM1 function and
that snm1 mutants process some DSBs normally.
Disruption of the b-lactamase domain of SNM1 prevents
function in ICL repair in vivo. The yeast SNM1 enzyme is
known to be a DNA 50-exonuclease (9), and disruption of
the b-lactamase domain destroys the exonuclease activity,
linking this function to ICL repair. Thus it seems that the
exonuclease must act in processing a speciﬁc structural
intermediate in ICL repair.
The SNM1 family is well conserved in mammals and
contains SNM1B/Apollo, SNM1C/Artemis, ELAC2 and
CPSF73 (1). The CPSF subunit hydrolyzes mRNA (10).
The mammalian orthologs all have the b-lactamase
domain preserved, suggesting hydrolytic function.
SNM1B/Apollo possesses a 50-exonuclease activity and
may play a role in telomere maintenance (11). Artemis
has been shown to be a 50-exonuclease interacting with
DNA-PKcs, which phosphorylates it, to gain a speciﬁc
endonucleolytic function cleaving DNA hairpin struc-
tures, such as formed by the RAG1/RAG2 functions (12).
That Artemis plays a role in V(D)J recombination and
immune competency was demonstrated by the ﬁnding that
some patients with radio-sensitive severe combined
immune deﬁciency (RS-SCID) are defective in Artemis
function (13–15).
No such functional role has been demonstrated for the
mammalian SNM1 gene. Disruption in mice produces
remarkably little phenotype (16). Embryonic stem (ES)
cells from mice with an Snm1 disruption show increased
sensitivity to MMC, but not to other DNA cross-linking
agents, including cisplatin or psoralen (16). Another
report found that SNM1 disruption alone or in combina-
tion with a p53 null mutation resulted in accelerated
tumorigenesis, as well as decreased survival of snm1 / 
mice (17). Murine embryonic ﬁbroblasts (MEFs) from
these mice show loss of a mitotic checkpoint and increased
sensitivity to spindle poisons (18). Thus the multiple
orthologs in mammals, along with the mild phenotype,
cloud the role of SNM1 protein in genome stability and
DNA repair. While human ﬁbroblasts depleted for SNM1
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data), without a deﬁned group of patients, the function of
SNM1 is unknown.
We have cloned the hSNM1 gene into an insect cell
system and overexpressed the recombinant protein. It
possesses a 50-exonucleolytic activity on single-stranded
DNA or RNA. The activity is reduced at least 97% on
double-stranded DNA or hairpin structures. The protein
functions as a monomer of  115kDa. Mutagenesis of
the conserved aspartate residue at position 736 to an
alanine inactivates the nucleolytic activity, indicating the
b-lactamase domain encodes the nuclease function.
MATERIALS AND METHODS
Cellculture andplasmid construction
Kc 167 insect cell line (Drosophila melanogaster) was
purchased from Drosophila Genomics Resource Center,
Indiana University, Indiana, and was grown in
Schneider’s Drosophila Medium (SDM) (Invitrogen,
Carlsbad, CA, USA) containing 10% fetal bovine serum
(HyClone, Logan, UT, USA).
A full-length hSNM1 cDNA clone was isolated from a
lymphoblast cDNA library (a gift from Dr Manuel
Buchwald), and sub-cloned into the expression vector
pAc5.1a (Invitrogen, Carlsbad, CA, USA) by PCR
ampliﬁcation of the coding region with primers tagged
with a Kozak sequence and compatible restriction sites
(MfeI and SmaI) (pAc5.1a-EcoRI and BstB1 + Klenow).
To make the hSNM1-D736A mutant construct, the
Quick-Change site-directed mutagenesis method was
followed as recommended (Stratagene, La Jolla, CA,
USA). Brieﬂy, mutant sense and antisense primers (50-C
ACACATTTTCATTCTGCTCATTATGCTGGATTGT
C-30, and 50-GACAATCCAGCATAATGAGCAGAAT
GAAAATGTGTG-30, respectively) were used in PCR
ampliﬁcation, with pAC5.1-hSNM1 as template and
Pfu-Turbo DNA polymerase (Stratagene, La Jolla, CA,
USA). The PCR product was digested with DpnI, and
transformed into chemically competent E. coli XL1-Blue
MRF0 cells (Stratagene, La Jolla, CA, USA). Colony PCR
followed by BclI digestion (the D736A mutation elim-
inates a BclI restriction site) was performed to identify the
mutant clones. The selected clones were then conﬁrmed by
sequencing.
Proteinexpression andpurification
Transfection of plasmids into Kc 167 cells was performed
using Cellfectin Transfection Reagent (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s
instructions. Brieﬂy, 10mg plasmid (pAc5.1-hSNM1 or
pAc5.1a control) was mixed with 50ml Cellfectin, and
incubated at room temperature for 30min. The mixture
was then added to 4 10
7Kc 167 cells, and incubated for
2h at room temperature. After the incubation, the
transfected cells were grown in SDM containing 5%
FBS for 3 days before the harvest.
The following steps were performed at 48C. The cells
were harvested by centrifugation, washed twice with PBS,
and resuspended in 500ml Buﬀer A (50mM NaPO4,p H
7.1, 300mM NaCl, 5mM imidazole, 1% IGEPAL CA
630, 10% glycerol, 5mM b-mercaptoethanol, 1mM
PMSF, 1mM sodium orthovanadate, 1mM sodium
ﬂuoride, 5mM sodium pyrophosphate, plus 1/100
volume Complete EDTA-free protease inhibitor cocktail
(Roche, Nutley, NJ, USA), rocked gently for 1min, then
incubated on ice for 10min. A cleared lysate was obtained
by centrifugation at 800 g for 10min at 48C. The cleared
lysate supernatant was then mixed with an equal volume
of 50% v/v slurry of TALON beads (Clontech, Mountain
View, CA, USA), pre-equilibrated in Buﬀer B (50mM
NaPO4, pH 7.1, 300mM NaCl, 10mM imidazole, 10%
glycerol, 5mM b-mercaptoethanol, 1mM PMSF), and
incubated at 48C for 2h with gentle rotation. The bound
beads were then poured into a Poly-Prep chromatography
column (Bio-Rad, Hercules, CA, USA), and unbound
proteins were allowed to ﬂow through by gravity. The
column was then washed with 20 bed volumes of Buﬀer B,
followed by 10 bed volumes of Buﬀer C (50mM NaPO4,
pH 7.1, 300mM NaCl, 20mM imidazole, 10% glycerol,
5mM b-mercaptoethanol, 1mM PMSF). Elution of
hSNM1 was performed by adding 4 bed volumes of
Buﬀer D (50mM NaPO4, pH 7.1, 300mM NaCl, 150mM
imidazole, 10% glycerol) and collecting 250ml fractions.
All the fractions were brought to a ﬁnal concentration
of 5mM DTT, frozen in liquid nitrogen, and stored
at –808C. Protein concentrations of the samples were
determined with protein assay dye reagent concentrate
(Bio-Rad, Hercules, CA, USA). Puriﬁcation fractions
were analyzed by SDS-PAGE followed by Coomassie
Blue, silver staining or western blotting.
Approximately 100–125mg of TALON-puriﬁed hSNM1
and hSNM1-D736A were further puriﬁed by gel ﬁltration
on Superose-6 or Superose-12 FPLC columns
(GE Healthcare, Piscataway, NJ, USA) equilibrated in
Buﬀer E (50mM NaPO4.H2O pH 7.1, 5mM DTT,
300mM NaCl, 5% glycerol). After a void volume of
8ml, a total of 40 0.5ml fractions were collected and
analyzed by SDS-PAGE followed by silver staining and
immunoblotting.
Immunoblotting
Approximately 20ml of each protein fraction was sepa-
rated by 8% SDS-PAGE, and transferred to Immobilon-P
PVDF membrane (Millipore, Billerica, MA, USA). After
blocking in PBST (PBS+0.1% Tween-20) with 5% non-
fat dry milk, the membrane was probed with anti-V5
monoclonal antibody (Invitrogen, Carlsbad, CA, USA)
diluted 1:5000 in PBST with 5% non-fat dry milk. The
blot was then incubated with goat anti-mouse IgG
horseradish peroxidase conjugated secondary antibody
(Calbiochem, San Diego, CA, USA) diluted 1:10000 in
PBST with 5% non-fat dry milk. Detection was by
Immobilon-Western Chemiluminescent HRP reagent
(Millipore, Billerica, MA, USA).
Substrates
Custom oligonucleotides (Integrated DNA Technologies
Inc., Coralville, IA, USA) were 20-dT (50-TTTTTTTTTT
TTTTTTTTTT); S-1 (50-GACCAAGGGGTACCAG);
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GTACCCCTTGGTC). Shorter oligo-dT substrates
(15-dT, 10-dT and 5-dT) were synthesized by the OHSU
Molecular Microbiology and Immunology Research Core
Facility. To make a 50 labeled ssDNA, 25pmol of 20-dT
was labeled with [g-
32P]-ATP, using T4 polynucleotide
kinase (New England Biolabs, Ipswich, MA, USA). To
make a 30 labeled ssDNA substrate 25pmol of 20-dT was
labeled with [a-
32P]-ATP-dideoxyadenosine triphosphate
using terminal deoxynucleotide transferase (New England
Biolabs, Ipswich, MA, USA). The 30-end-labeled
substrate was then phosphorylated with cold ATP and
T4 polynucleotide kinase or left unphosphorylated at the
50-end. The internally labeled dsDNA (42bp) was made by
50 phosphorylating S-1 with cold ATP and T4 polynucleo-
tide kinase, then annealing to 15pmol S-2. The duplex was
then extended with Klenow polymerase with dATP,
dTTP, dGTP and [a-
32P]-dCTP. Unincorporated radio-
nucleotides were removed by ProbeQuant G-50 micro
columns (Amersham Biosciences, Piscataway, NJ, USA).
A pseudoﬂap substrate was constructed by annealing
50-end-labeled cru-13 (50-CTCCATCCAAGGAGTTGGC
GATCACGAAGCTTTAATCTGGAGCCA) with
cru-14 50-TCCAGATTAAAGCTTCGTGATCGACC
GAGGTCCAAGAACTC). Hairpin and hairpin-loop
substrates were generated with oligonucleotides HP-1
(50-CCACTGCGTCTAAGGTGGAGGTGAACGTTCA
CCTCCACCTTAGACG) and HP-loop (50-CCACTGCG
TCTAAGGTGGAGGTGAACTTTTTTTTTTGTTCAC
CTCCACCTTAGACG), respectively, and labeling with
[a-
32P]-dCTP and Klenow polymerase. This strategy
incorporated a single 30-[
32P]-C, and left the 50-end
unphosphorylated, thus protecting the 50-end from
exonucleolytic attack during the assay. A single-strand
RNA substrate (50-UGCCUUCCACCUCCACCAATT)
was labeled at the 50-end with polynucleotide kinase and
[g-
32P]-ATP, as for the 20-dT substrate.
In vitro nucleaseassay
The assay was similar to an assay for yeast SNM1 (9)
Brieﬂy, 0.5pmol of radiolabeled substrate was combined
with indicated amounts of puriﬁed protein (see
the ﬁgure legends) in 15mlo f1   Buﬀer F (50mM Tris-
acetate pH 7.2, 10mM Mg acetate, 75mM Potassium
acetate, 1mM DTT) supplemented with 100mg/ml BSA,
and incubated at 378C for 20min. For control reactions,
10 units of Rec-Jf or -exonuclease (for double-stranded
substrate) (New England Biolabs, Ipswich, MA, USA)
were used as recommended by the supplier. The reactions
were stopped by adding an equal volume of formamide gel
loading buﬀer (95% formamide, 20mM EDTA pH 8.0,
0.04% xylene cyanol, 0.04% bromophenol blue) and
heating at 658C for 20min. DNA was resolved on a 12%
denaturing polyacrylamide gel. Greater resolution was
obtained with 16% acrylamide gels, as indicated in
the ﬁgure legends. The gel was wrapped in Saran wrap
and analyzed by autoradiography. One unit of enzymatic
activity is deﬁned as the release of 1pmol of
32Pa s
mononucleotide in 10min at 378C.
RESULTS
Overproduction ofhSNM1 isnot stablein human fibroblasts
In order to isolate and purify hSNM1, the cDNA for
SNM1 (GenBank D42045) was synthesized by PCR and
cloned into a pIRES vector system with a 30-V5 epitope
and 6xHis tag (Figure 1A). This construct was transfected
into human ﬁbroblasts. Production of the SNM1 protein
was veriﬁed by immunoblot analysis for the V5 epitope
(Figure 1B), and the cells were continued on selection with
puromycin. After fourteen days the cells remained
puromycin resistant, but the expressed protein was
absent by immunoblot (Figure 1B). Comparison of over
12 independent transfections, with subsequent culture,
showed that hSNM1 expression was lost in each case by
two weeks. The overall transfection eﬃciency of the
SNM1 construct was poor, suggesting it had a deleterious
eﬀect on cell growth. Thus, apparently the SNM1 protein
is not tolerated at an increased or unregulated level in
human ﬁbroblasts. Our ﬁnding is in agreement with the
observations of others, suggesting that SNM1 is toxic
(16,19). Intolerance of overexpression of SNM1 is in
contrast to lack of the protein, which is well tolerated.
Overproduction ofhSNM1 inan insect cell system
In light of the ﬁnding that hSNM1 cannot be stably
overproduced in human cells, we turned to a diﬀerent
expression system. The hSNM1 coding sequence was
cloned into pAc5.1 behind an insect cell promoter, Ac5
(Figure 1A). The 30-epitopes allowed tracking the protein
puriﬁcation by immunoblot (Figure 1C). The column
puriﬁcation (immobilized metal ion aﬃnity chromatogra-
phy, IMAC) was done by passing a cleared cell lysate over
the matrix in low imidazole (5 to 10mM), followed by
washes with 20mM imidazole and elution with buﬀer
containing 150mM imidazole. The peak of the activity
and epitope tag typically eluted in the second and third
fractions, indicating a uniform binding and elution pattern
for the 6xHis tag; there was slight batch-to-batch variation
in the relative amount of SNM1 protein in peak elution
fractions, most likely due to the small scale of the
puriﬁcations and the manual elution and collection of
the fractions.
hSNM1has single-strand 50-exonuclease activity requiring a
phosphate
With a single-stranded substrate 20 bases in length,
with a 50-
32P label (9) the hSNM1 protein manifests
50-exonuclease activity, similar to that reported for yeast
SNM1 and Artemis (12) (Figure 1D). The RecJf single-
strand 50-exonuclease of E. coli served as a control (20).
Since the assay measures only the removal of the
50-nucleotide containing the label, and since the product
migrates at the position of a mononucleotide,
the exonuclease acts by removing the terminal
mononucleotide. As insect cells are known to contain
endogenous exonucleases, control puriﬁcations with
mock-transfected cells were done in parallel to ensure
that the IMAC elution fractions were free of endogenous
exonuclease activity (Figure 1D, lane 12). A gel
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from IMAC is shown (Figure 1E) along with an
immunoblot to detect the V5 epitope. No intrinsic cross-
reacting material was detected, verifying the position of
the hSNM1 protein.
The hSNM1 exonuclease functions best at slightly
alkaline pH and low salt (Figure 2A), and is dependent
on Mg
2+, showing no activity in excess EDTA, Fe
3+ or
Zn
2+. The activity is inhibited by ATP or NEM,
indicating requirement for cysteine residues and suggest-
ing the catalytic site binds phosphate. The 50-exonuclease
acts equally well on longer length substrates,
including 40-mers (data not shown). Partial reactions
with 50-labeled substrate yielded single-nucleotide
product and no other intermediates (Figures 1D and
2A); therefore, the enzyme has no apparent endonucleo-
lytic activity.
To evaluate whether the activity is able to hydrolyze
DNA from the 30-terminus, a substrate was constructed
with the
32P label at the 30-end. The hSNM1
enzyme does not hydrolyze substrate detectably from
the 30-terminus. This test also showed that the
exonuclease activity strictly requires a 50-phosphate
group (Figure 2B), whereas the RecJf enzyme is
active without a 50-phosphate group, although with
reduced activity. The ﬁnal product for hSNM1 is in the
range of 6–8nt, indicating that the exonuclease
hydrolyzes from the 50-terminus, with much decreased
aﬃnity for the substrate once the oligonucleotide is
shorter than an octamer (Figure 2B, lane 6). Better
resolution of the reaction was obtained by running
the reaction products on a 16% acrylamide–42% urea
gel (Figure 2C) using an equimolar mix of 50-labeled
oligonucleotides diﬀering by 5nt in length. The reaction
went nearly to completion with the 20-dT substrate,
the 15-dT was  75% digested, the 10-dT substrate was
digested 520% and there was no detectable digestion of
the 5-dT substrate, supporting loss of binding for short
substrates (Figure 2B, lane 6). At this resolution, the
single-nucleotide product clearly co-migrated with the
product of the RecJf reaction verifying that the product
is a mononucleotide. On the 16% gel, the products
of digestion of a 30-labeled substrate migrated as a
ladder with single-nucleotide spacing ranging from
6 to 20nt (Figure 2C, lane 7). A 50-phosphate is required
(Figure 2C, lane 9).
Figure 1. Aﬃnity puriﬁcation of His-tagged hSNM1Protein. (A) pAc5.1-hSNM1 and pIRESpuro-hSNM1 constructs. (B) Immunoblot of HEK293
cells transfected with pIRESpuro-hSNM1; 25mg total protein loaded per lane. (C) Immunoblot of hSNM1-V5His fractions from IMAC. Lane 5 is an
elution fraction 2 from mock-transfected cells, carried out in parallel. (D) Assay of hSNM1-V5His fractions for 50 exonuclease activity. Lanes: 1,
RecJf; 2, Substrate alone; 3, Cleared lysate; 4, Flowthrough; 5, Wash 2; 6–11, Elution fractions 1–6; 12, IMAC fraction 2 from mock-transfected Kc
167 cells. (E) Silver stained SDS-PAGE of pAc5.1-SNM1-transfected KC167 cleared lysate (WCE), and IMAC elution fraction 2, alongside an anti-
V5 western blot of IMAC elution fraction 2.
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The overproduction and IMAC puriﬁcation of hSNM1
produces over 1000-fold puriﬁcation as measured by
the exonuclease assay (Table 1). This would represent
a lower estimate due to mixed nuclease and phos-
phatase activities in the extract. IMAC puriﬁed hSNM1
fraction 3 was fractionated on a gel ﬁltration column for
further puriﬁcation and to estimate the apparent
molecular weight of the active species. Elution of the
detectable epitope tag occurred at a position consistent
with the molecular weight of 115kDa for hSNM1
[range 130–200kDa] (Figure 3A). 50-Exonuclease activity
was detected in a peak centered around the same
fraction (Figure 3B). Therefore it appears most likely
that the activity of hSNM1 occurs in monomer form.
Speciﬁc activity was determined by serial dilution of an
active fraction, as shown in Figure 4. The puriﬁcation,
by speciﬁc activity, after Superose chromatography
was greater than 5-fold over the IMAC eluate (Table 1).
hSNM1does nothydrolyze double-strand DNA
The hSNM1 50-exonucleolytic activity was tested on
double-strand DNA. In order to avoid over-estimating
the activity due to ‘breathing’ of the duplex termini,
an internal label was used.  exonuclease, active on
double-strand DNA was used as a control (Figure 4).
ySNM1, as reported (9), shows activity on the double-
strand substrate, but hSNM1 activity is reduced to  1%
of that on single-strand DNA (Table 1). Results for
IMAC-puriﬁed hSNM1 (Figure 4A and B) were compa-
rable to the further-puriﬁed Superose 6 active fraction
(Figure 4C and D).
hSNM1is inactivated withloss ofaconserved aspartate
residue
Mutagenesis of the aspartate at residue 252 in a conserved
domain in the yeast SNM1 protein inactivates the
Figure 2. Characterization of hSNM1. (A) hSNM1 activity requires Mg
2+ as a cofactor. 50-end-labeled substrate was tested with IMAC fraction 2
and various buﬀers. Lanes: 1, RecJf control; 2, Substrate only control; 3, Buﬀer F (see Materials and Methods section); 4, Buﬀer F, as for lane 3,
but 2-fold dilution; 5, Buﬀer P, (10mM NaPO4, 10mM MgCl2, 1mM DTT), pH 6.4 (100mM NaCl); 6, Buﬀer P, pH 7.2 (100mM NaCl); 7,
Buﬀer P, pH 7.2 (50mM NaCl); 8, Buﬀer P, pH 7.2 (15mM NaCl); 9, Buﬀer P, pH 7.2 (No NaCl); 10, Buﬀer P, pH 7.2 (100mM NaCl, 2mM
ZnCl2); 11, Buﬀer P, pH 7.2 (100mM NaCl, 0.1mM FeCl3); 12, Buﬀer P, pH 7.2 (100mM NaCl, 20mM EDTA); 13, Buﬀer P, pH 7.2 (100mM
NaCl, 2mM N-ethyl maleimide); 14, Buﬀer P, pH 7.2 (100mM NaCl, 1mM ATP) (B) Assay of 30-end-labeled substrate. Lanes 1–3, 30-end-labeled,
50-non-phosphorylated substrate; lanes 4–6, 30-end-labeled, 50-phosphorylated substrate. Lanes: 1 and 4, RecJf; 2 and 5, NEB2 Buﬀer only; 3 and 6,
 140ng IMAC-puriﬁed hSNM1. (C) Exonuclease assays comparing 50-phosphorylated and 50-unphosphorylated substrates. Assays used  140ng
IMAC-puriﬁed hSNM1, and were incubated 60min at 378C. Controls consisted of substrate and buﬀer only. The substrate in lanes 4 and 5 was an
equimolar mix of 50-labeled 5-dT, 10-dT, 15-dT and 20-dT (the 5-dT oligo did not label well with polynucleotide kinase). Products were resolved on a
16% acylamide–42% urea gel.
Table 1. Comparative analysis of hSNM1 on ssDNA and dsDNA
substrates
Protein
concentration
(mg/ml)
Total
protein
Speciﬁc activity (u/mg)
ssDNA dsDNA
Cleared lysate 20.7 10.4mg 55
  ND
IMAC fraction 2 0.070 17.5mg 1.5 10
4 1.8 10
2
FPLC 50.005 52.5mg 48 10
4 46 10
2
ND=not determined.
 Speciﬁc activity of mock-transfected cleared lysate was not signiﬁ-
cantly diﬀerent from pAc5.1-hSNM1-transfected cleared lysate, due to
endogenous nuclease activity.
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in hSNM1, was changed to an alanine (Figure 5A).
The mutant protein was expressed normally and at
appropriate molecular weight as veriﬁed by anti-V5
immunoblot (Figure 5B). However, the expressed protein
did not have detectable activity in the standard assay, even
with overloading (Figure 5C). Thus the b-lactamase
domain is required for the 50-exonuclease function. This
observation is in agreement with ﬁndings for ySNM1 and
demonstrates a functional basis in the conservation. The
absence of mononucleotide product in fractions 1–3 of
the D736A protein (Figure 5C, lanes 5–7) underscores
the lack of a contaminating insect cell exonuclease.
The exonuclease also hydrolyzes single-strand RNA to
approximately the same extent as DNA (Figure 6D).
hSNM1 hasno intrinsic endonuclease activity on flap or
hairpin substrates
Due to the homology between hSNM1 and Artemis, and
the ability of Artemis to incise single-stranded DNA at
junctions between single strands and double strands, in
association with DNA-PKcs (12), hSNM1 was tested with
various substrates to see if it could make similar incisions.
A pseudoﬂap structure consisting of two annealed
oligonucleotides sharing 23bp of complementarity and
18nt of non-complementary bases was incubated with
hSNM1 over a 30-min time course (Figure 6A). Whereas
hSNM1 removed the 50 label as a single nucleotide, there
was no evidence for the generation of a 23-mer
intermediate. Similarly, a 21-bp hairpin substrate and a
21-bp hairpin with a 10nt loop were not incised by
hSNM1 (Figure 6B), in contrast to Exo 1 from yeast (21).
Taken together, this suggests that hSNM1 has no single-
strand endonucleolytic activity. This does not preclude the
possibility of activation by post-translational modiﬁcation
or interaction with a partner protein, but at face value
hSNM1 appears to be a purely single-strand exonuclease.
DISCUSSION
The hSNM1 protein has been overproduced in an insect
cell vector system and partially puriﬁed, with deﬁnition of
a single-stranded DNA 50-exonclease activity, dependent
on the conserved b-lactamase domain. Thus the protein
shares the basic activity of its orthologs, ySNM1 and
Artemis, which show 50-exonuclease activity. Other
members of the b-CASP family, CPSF73 and CPSF100,
process the 30 termini of mRNA (22). As described above,
Figure 3. Gel ﬁltration of hSNM1. (A) Immunoblot of Superose 6
fractions. IMAC fraction 3 was further puriﬁed on a Superose 6
column as described in Materials and Methods section. (B) Assay
of Superose 6 fractions 11–17. Lanes: 1, RecJf control; lane 2,
substrate only.
Figure 4. hSNM1 is a single-strand-speciﬁc exonuclease. (A) Assay of hSNM1 IMAC fraction 3 on 20-dT substrate. Lanes: 1, RecJf; 2, substrate
only; 3, ySNM1; Lanes 4, 116ng protein 5, 29ng protein; 6, 7.25ng protein; 7, 1.8ng protein; 8, 0.45ng protein. (B) Assay of IMAC fraction 2 on
internally labeled double-stranded substrate. Lanes: 1,  exonuclease control; 2, ySNM1; 3, 140ng protein; 4, 35ng protein; 5, 4.4ng protein.
(C) Assay of FPLC fraction 16 on 20-dT substrate. Lanes: 1, substrate only; 2, RecJf control; 3, fraction 16 ( 10ng); 4,  2.5ng; 5,  0.65ng; 6,
 0.17ng. (D) Assay of FPLC fraction 16 on internally labeled ds substrate. Lanes: 1, fraction 16 ( 10ng); 2,  2.5ng; 3,  0.65ng.
6120 Nucleic Acids Research, 2007, Vol. 35, No. 18Figure 5. hSNM1 requires a conserved domain and also digests RNA. (A) Alignment of human and yeast SNM1 proteins in the vicinity of a
conserved aspartate which is required for exonuclease function. (B) Immunoblot of hSNM1 D736A mutant protein and wild-type IMAC fractions,
performed in parallel. Lanes: CL, cleared lysate; M, Markers; FT, Flowthrough. (C) Assay of D736A IMAC fractions. Lanes: 1, RecJf control; 2,
substrate alone; 3, ySNM1; 4, Cleared lysate; 5–7, eluates 1–3. (D) Assay of IMAC-puriﬁed wild-type and D736A mutant hSNM1 (fraction 2) with a
single-strand RNA substrate.
Figure 6. hSNM1 does not cleave pseudoﬂap structures or hairpins. (A) Timecourse of digestion of pseudoﬂap. There is no endonucleolytic
activity at the ss–ds junction. (B) Assay of hSNM1 with hairpin substrates. Control reactions with the standard 50-labeled 20-dT substrate
went virtually to completion, whereas no intermediate-sized products were released from the hairpin substrates; for comparison, S1 nuclease released
a 20-mer endonucleolytic product from the hairpin-loop substrate. Samples were boiled prior to loading and analyzed on a 16% denaturing
acrylamide gel.
Nucleic Acids Research, 2007, Vol. 35, No. 18 6121mutation of a conserved site in the b-lactamase domain
(D736A) inactivates the 50-exonuclease activity.
Mutagenesis of the same site (D37N) in Artemis, changing
an aspartate to asparagine, caused loss of the DNA-PKcs
endonuclease activity of the protein, but did not cause loss
of the 50-exonuclease activity (23). The discrepancy for
loss of the exonuclease may reﬂect the diﬀerent amino acid
substitutions, or it may reﬂect a fundamental diﬀerence in
structure and activity of the two proteins.
The ySNM1 protein is known to act in ICL repair
after incision (unhooking) at the site of the ICL, and to be
required for reformation of the intact strand of DNA.
It is possible that the yeast enzyme is involved in terminus
modiﬁcation of intermediates in the ICL repair pathway,
facilitating strand rejoining (9). The EXO1 enzyme of
yeast, involved in several DNA processing pathways in
yeast is also a 50 exonuclease (21). Therefore the activity
of hSNM1 is a candidate to be involved in modifying
termini at the site of DNA repair. Since hSNM1 is
speciﬁc for single-stranded DNA, such a substrate might
be generated during the repair of DNA interstrand cross-
links, possibly in concert with a helicase, analogous to
what has been suggested for Exo1 and WRN or RecQ1
(24,25).
There is no deﬁned group of patients defective in
hSNM1, nor is there an easily identiﬁable defect in
DNA repair in animal models lacking SNM1. This may be
due to the existence of multiple closely related members of
the b-CASP family, SNM1A, SNM1B and Artemis.
Disruption of SNM1B in chicken DT40 cells renders
them sensitive to cisplatin, and a double disruption of
SNM1A and SNM1B is additive, suggesting that
SNM1B may be a redundant function in ICL repair
(26). A knockdown of hSNM1B/Apollo also sensitized
human cells to cross-linking agents as well as ionizing
radiation (27). hSNM1B/Apollo was recently character-
ized as a 50-exonuclease interacting with TRF2 in telomere
maintenance, suggesting that hSNM1 and hSNM1B/
Apollo may have partially overlapping functions (11,28),
but that their association with diﬀerent proteins or
complexes may determine the pathway in which they
operate. In view of these results collectively, identiﬁcation
of a phenotype in animal models lacking SNM1 may
require multiple deﬁciencies. While hSNM1 has not been
shown to be signiﬁcant for cell survival with multiple
DNA cross-linking agents, we have found that its
deﬁciency leads to chromosome breaks and radial forma-
tion, an index of genome instability with ICL formation
(unpublished data).
We found no evidence for phosphorylation of the
protein (data not shown). This does not eliminate the
possibility that modiﬁcation of SNM1 occurs in human
cells with DNA damage. The enzyme reported here was
recombinant and produced in insect cells and so may not
reﬂect the state of hSNM1 in human cells, with or without
damage. Artemis is notably modiﬁed, acquiring an
endonucleolytic activity cleaving putative recombination
intermediates when phosphorylated and bound by
DNA-PK. Thus it is possible that we observed only one
activity associated with hSNM1.
The hSNM1 protein cannot be stably overproduced in a
human cell. Since disruption of SNM1 has been reported
to alter a mitotic checkpoint (18), it may be that
overproduction is lethal to the cell due to disruption of
the mitotic checkpoint. Alternatively, since we demon-
strate here that SNM1 is a 50-exonuclease, it is possible
that overexpression is destroying an intermediate in
normal DNA processing, leading to genome instability.
If SNM1 is modiﬁed in human cells, then it might be that
the modiﬁed form possesses an additional activity, which
is deleterious when overexpressed.
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